Active, not recruitingPhase 3NCT05064878
A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder
Studying CDKL5-deficiency disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zogenix, Inc.
- Principal Investigator
- UCB Cares001 844 599 2273
- Intervention
- ZX008 (Fenfluramine Hydrochloride)(drug)
- Enrollment
- 87 enrolled
- Eligibility
- 1-35 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Ep0216 154, Birmingham, Alabama, United States
- Ep0216 144, Los Angeles, California, United States
- Ep0216 101, San Francisco, California, United States
- Ep0216 173, Aurora, Colorado, United States
- Ep0216 149, Washington D.C., District of Columbia, United States
- Ep0216 157, Atlanta, Georgia, United States
- Ep0216 113, Boston, Massachusetts, United States
- Ep0216 134, Detroit, Michigan, United States
- Ep0216 166, Chapel Hill, North Carolina, United States
- Ep0216 164, Cleveland, Ohio, United States
- Ep0216 120, Philadelphia, Pennsylvania, United States
- Ep0216 124, Memphis, Tennessee, United States
- Ep0216 171, Austin, Texas, United States
- Ep0216 2505, Linz, Austria
- Ep0216 804, Brussels, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05064878 on ClinicalTrials.govOther trials for CDKL5-deficiency disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06448663Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)University of Milan
- ACTIVE NOT RECRUITINGNCT05373719Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency DisorderLoulou Foundation
- RECRUITINGNCT05558371International CDKL5 Clinical Research NetworkUniversity of Colorado, Denver